Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
22 sep 2010 - 23:31
Statutaire naam
Crucell N.V.
Titel
DSM and Crucell Announce Expansion of PERCIVIA PER.C6® Biopharmaceutical Joint Venture.doc
Bericht
DSM and Crucell Announce Expansion of PERCIVIA PER.C6® Biopharmaceutical Joint Venture
Heerlen/Leiden, the Netherlands (September 22, 2010) – Royal DSM N.V., the global Life Sciences and Materials Sciences company, and Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX), both headquartered in the Netherlands, today announced an expansion of the activities in their existing joint venture, the PERCIVIA PER.C6® Development Center (Cambridge, Massachusetts, United States), to transform the company from a development center into a full biopharmaceutical company for the development of PER.C6®-based biobetter proteins and monoclonal antibodies as well as global licensing of the PER.C6® human cell line for production of third party monoclonal antibodies and other proteins.
Datum laatste update: 28 juli 2024